Cayman Chemical Company is dedicated to Helping Make Research Possible by working with centers such as the UAMS Center for Drug Addiction and Response to identify emerging drugs of abuse. Collaborations such as these allow Cayman scientists to expeditiously synthesize reference standards, and to develop novel research tools to assist the forensic and academic communities to better understand the epidemic of designer drug abuse. As a company rooted in eicosanoid research with a strong background in cannabinoid research, medicinal chemistry, and assay development; Cayman Chemical is uniquely suited to meet the challenges of studying modern drugs of abuse.
Cayman Chemical’s 100,000 square foot FDA and DEA-inspected facility in Ann Arbor, Michigan, produces high-purity Schedule I-V controlled substances and is the leading provider of designer drug reference standards. Reference standards are available from Cayman’s ISO/IEC 17025:2005 and ISO Guide 34:2009 accredited laboratory and include parent compounds, their metabolites, isomers and degradants. These standards are used to further the development of methods of detection, and are used to better understand the associated toxicological and pharmacological effects of abused drugs. Please visit Cayman Chemical to learn more about our products, services, and published research on designer drugs of abuse.